Stereotactic Radiation Therapy for Oligo-Progressive Non-Small Cell Lung Cancer (STOP-NSCLC): A Randomized Phase II Trial
A multicentre randomized phase II trial of stereotactic body radiation therapy for
oligo-progressive non-small cell lung cancer. Eligible patients will be randomized in a 1:2
ratio between receiving their standard of care therapy or stereotactic ablative radiation therapy
(SABR) to all sites of oligo-progressive lesions.Radiotherapy will be administered as soon
as possible following randomization, and subjects will be followed until next disease
progression. The primary outcome is progression-free survival (PFS).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society